BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 9736048)

  • 1. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
    Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
    Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.
    Sigamani E; Wari MN; Iyer VK; Agarwala S; Sharma A; Bakhshi S; Dinda A
    Pediatr Surg Int; 2013 Mar; 29(3):223-7. PubMed ID: 23292539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination.
    Coppes MJ; Bonetta L; Huang A; Hoban P; Chilton-MacNeill S; Campbell CE; Weksberg R; Yeger H; Reeve AE; Williams BR
    Genes Chromosomes Cancer; 1992 Nov; 5(4):326-34. PubMed ID: 1283321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
    Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
    Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
    Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
    Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutional and somatic mutations in the WT1 gene in Wilms' tumor patients.
    Nordenskjöld A; Friedman E; Sandstedt B; Söderhäll S; Anvret M
    Int J Cancer; 1995 Nov; 63(4):516-22. PubMed ID: 7591260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
    Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identical genetic changes in different histologic components of Wilms' tumors.
    Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
    J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
    J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K; Fleming S
    Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal pathology in WAGR syndrome.
    Ariel I; Abeliovich D; Bar-ziv J; Hochberg A
    Pediatr Pathol Lab Med; 1996; 16(6):1013-21. PubMed ID: 9025899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
    Cowell JK; Groves N; Baird P
    Br J Cancer; 1993 Jun; 67(6):1259-61. PubMed ID: 8390282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.